NJ-OPEX
8.6.2022 09:02:06 CEST | Business Wire | Press release
OPEX® Corporation, a global leader in Next Generation Automation for almost 50 years, is introducing leading-edge Document and Mail Automation technology on 22 June 2022 to attendees of the Association for Intelligent Information Management (AIIM) Forum Europe in London.
OPEX’s new Gemini™ high-volume scanner is “Right-Speed™,” an unrivaled scanning capability that enables different types of documents to be scanned at different speeds without changing equipment to maximize throughput and operational efficiency.
“Gemini scans the widest range of document types, sizes and conditions—and handles them at the right speed for the job,” said Scott Maurer, President, OPEX International. “Whether documents need to be scanned at high speed, packet speed or drop feed, Gemini is the most versatile scanner available.”
With scan speeds of up to 240 pages per minute, the Gemini scanner features a dual-feeder design and the ability for continuous feeding. Its five programmable sort bins enable unique sorting capabilities and easy document handling. Other features include software configurability, scalability for the future, best-in-class service, and an ergonomic, customizable work area designed to enhance operator comfort and productivity.
Ideal for service bureaus, BPOs, government institutions, tax entities, medical records companies, insurance agencies, law firms, and a host of other industries, the Gemini scanner with “Right-Speed” technology was first unveiled in April in the U.S. during the 2022 AIIM Conference in Denver, Colorado.
“We are excited to showcase the Gemini scanner and ‘Right-Speed’ technology to customers across Europe who are looking for document automation solutions to solve their most pressing business challenges,” said Maurer. “We have been expanding our facilities, personnel and infrastructure to meet the growing automation needs of customers in Europe and around the world.”
An AIIM Forum Europe Partner, OPEX will be the only company demonstrating equipment live at the event.
In the coming months, OPEX will be able to demonstrate the Gemini scanner and “Right-Speed” technology at company facilities in Germany, France and the U.K. Customers who do not wish to travel in person can attend private webinars to learn about the Gemini scanner and the rest of OPEX’s existing Document and Mail Automation portfolio, which includes the Falcon® Series of high-volume, one-touch scanners that eliminate or significantly reduce prep time.
With generations of industry expertise, a proven track record developing first-class automation capabilities and advanced engineering, and a heritage of excellence, OPEX continuously reimagines automation technology to help clients solve their most significant business challenges today and in the future. For nearly five decades, OPEX has served as a trusted partner, collaborating closely with clients to develop customized, scalable solutions.
OPEX is vertically integrated—innovating, engineering, manufacturing, selling, and servicing all its automated solutions. This translates to the highest degree of quality equipment, reliable operations, product longevity, and an exceptional client experience.
To learn more, please visit OPEX.com .
About OPEX
OPEX Corporation
is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,500 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005195/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom